NEW YORK (GenomeWeb News) – As Venaxis prepares a submission to the US Food and Drug Administration for its appendicitis diagnostic test and a full European launch, the company announced this week the completion of the first futility analysis of the test.

As a result, an independent body has recommended a continuation of Venaxis' pivotal clinical trial for the test, called the APPY1 Test. The trial will include a second futility analysis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.